Table 2

Effect of rhIL-12 therapy on PBL subsets of cancer patients

Values are the mean ± SD of the absolute number (cells/μl) of total lymphocytes or lymphocytes expressing CD3 (total T cells), both CD3 and CD4 (CD4 T cells), both CD3 and CD8 (CD8 T cells), CD20 (B cells), or CD16 and/or CD56 in the absence of CD3 (NK cells) in peripheral blood drawn just before, 24 h after, or 14 days after a single i.v. bolus injection of rhIL-12 at a dose of 500 ng/kg.
Lymphocyte subsetBefore rhIL-1224 h after rhIL-1214 days after rhIL-12
Total lymphocytes1731 ± 992338 ± 2291677 ± 891
Total T cells1259 ± 636274 ± 1821283 ± 702
CD4 T cells932 ± 584236 ± 176878 ± 653
CD8 T cells299 ± 16633 ± 22347 ± 169
B cells229 ± 23431 ± 34179 ± 169
NK cells166 ± 1217 ± 6180 ± 110